Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct‐acting antiviral therapies
Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct‐acting antiviral therapies
复制标题
DOI：
10.1111/jgh.15224
复制
发表时间：
2020-08
影响因子：
4.1
通讯作者：
Hirohito Yoneyama;A. Morishita;H. Iwama;Koji Fujita;T. Masaki;J. Tani;Tomoko Tadokoro;T. Nomura;Teppei Sakamoto;K. Oura;Kei Takuma;Mai Nakahara;Shima Mimura;Akihiro Deguchi;M. Oryu;Kunihiko Tsutsui;T. Himoto;K. Shimotohno;T. Wakita;H. Kobara;Tsutomu Masaki
中科院分区：
文献类型：
--
作者：
Hirohito Yoneyama;A. Morishita;H. Iwama;Koji Fujita;T. Masaki;J. Tani;Tomoko Tadokoro;T. Nomura;Teppei Sakamoto;K. Oura;Kei Takuma;Mai Nakahara;Shima Mimura;Akihiro Deguchi;M. Oryu;Kunihiko Tsutsui;T. Himoto;K. Shimotohno;T. Wakita;H. Kobara;Tsutomu Masaki
直接作用抗病毒(DAA)疗法已被证明在没有耐药相关替换(RAS)的情况下对根除丙型肝炎病毒(HCV)非常有效。然而，即使在没有检测到RAS的情况下，治疗有时也会失败，这表明存在一些宿主相关因素参与了DAA根除丙型肝炎。为了探讨这些因素，我们分析了接受DAA治疗的患者的血清microRNAs(MiRNAs)。
Direct‐acting antiviral (DAA) therapies have been proven to be highly effective for the eradication of hepatitis C virus (HCV) without resistance‐associated substitutions (RASs). However, even in cases with no detected RASs, treatment sometimes fails, suggestive of the existence of some host‐related factors involved in HCV eradication by DAAs. To explore such factors, we analyzed the serum microRNAs (miRNAs) of patients who received DAA treatment.